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Plaque reduction neutralisation tests (PRNT), micro-
neutralisation (MN), Middle East respiratory syn-
drome (MERS)-spike pseudoparticle neutralisation 
(ppNT) and MERS S1-enzyme-linked immunosorbent 
assay (ELISA) antibody titres were compared using 95 
sera from 17 patients with MERS, collected two to 46 
days after symptom onset. Neutralisation tests cor-
related well with each other and moderately well with 
S1 ELISA. Moreover to compare antigenic similarity of 
genetically diverse MERS-CoV clades, the response of 
four sera from two patients sampled at two time peri-
ods during the course of illness were tested by 90% 
PRNT. Genetically diverse MERS-CoV clades were anti-
genically homogenous.
Introduction
Middle East respiratory syndrome (MERS) poses a 
major threat to global public health [1]. Validated sero-
logical assays are important for diagnosis and for 
seroepidemiology to define prevalence and risk fac-
tors [2,3]. Serological assays for detecting antibody 
for MERS-coronavirus (CoV) infection include anti-
body arrays, enzyme-linked immunosorbent assay 
(ELISA), immune-fluorescence, microneutralisation 
(MN), plaque reduction neutralisation (PRNT) and 
MERS-spike pseudoparticle neutralisation tests (ppNT) 
[2,4-6]. While data from individual case reports exist 
[6], there are limited comparative data on serological 
methods for detecting MERS-CoV antibody in humans, 
because of a lack of well-characterised sera [7]. We 
used 95 sera from 17 patients with real-time reverse 
transcription polymerase chain reaction (RT-PCR) con-
firmed MERS-CoV infection diagnosed during an out-
break of MERS in South Korea [8,9] to compare PRNT 
antibody titres using 90% (PRNT90) and 50% (PRNT50) 
plaque reduction end points, MN, MERS-spike ppNT 
and S1-ELISA tests. The sera were also used to investi-
gate the antigenic similarity of three genetically diverse 
strains of MERS-CoVs [10]. We had previously reported 
that early PRNT50 and S1-ELISA antibody responses in 
this patient-cohort were associated with improved clin-
ical outcome [9].
Methods
Patients
Patients with RT-PCR confirmed MERS-CoV infections 
admitted to Seoul National University (SNU) Hospital, 
SNU Boramae Medical Center and SNU Bundang 
Hospital within the first 14 days after onset of ill-
ness during the outbreak of MERS-CoV between May 
and June 2015 in South Korea were included. Serial 
serum samples (n = 95 in total) were collected from 17 
patients during the first 39 days of illness or up to time 
of discharge from hospital. This study was approved by 
the Institutional Review Board of SNU. Clinical data on 
these patients have been previously reported [9].
Viruses
The MERS-CoV strains used in the virus neutralisation 
assays belonged to clade A (MERS-CoV-strain EMC), 
clade B (dromedary camel MERS-CoV Al-Hasa FKU-
HKU13 2013) as well as a virus from a distinct non A 
and B clade (dromedary camel Egypt NRCE-HKU 270 
2013) as previously described [10].
Serology tests
The sera were heat-inactivated for 30 min at 56 °C 
before testing. The PRNT assays were performed in a 
24-well format in duplicate for each serum dilution. 
Twofold serum dilutions were incubated with 40 to 60 
plaque-forming units of virus for 1 hour at 37 °C. The 
virus – serum mixture was added onto a Vero cell mon-
olayer and incubated for 1 hr at 37 °C in a 5% CO2 incu-
bator. Then, the supernatant was removed and the cells 
overlaid with 1% agarose (SeaKem LE Agarose, Lonza, 
2 www.eurosurveillance.org
Switzerland) in cell culture medium (Minimum Essential 
Medium with 2% fetal bovine serum). The plates were 
fixed and stained after three days incubation. Antibody 
titres were defined as the highest serum dilutions that 
resulted at ≥ 50% (PRNT50) and ≥ 90% (PRNT90) reduction 
in the number of plaques, respectively.
The ppNT assays were performed as previously 
described, with triplicate serum dilutions [5,11]. MN 
tests were carried out to determine the highest serum 
dilution that suppressed virus cytopathic effect in Vero 
cells following infection with a virus dose of 100 tis-
sue culture infection dose50 mixed with the respec-
tive serum dilution [5]. Serum dilutions were done in 
quadruplicate. Positive and negative controls and virus 
back-titrations were included in each assay. Antibody 
titres of ≥ 1:20 were regarded as positive.
The S1 ELISA EI 2604–9601G kit was purchased from 
EUROIMMUN Luebeck, Germany for detection of human 
IgG against MERS-CoV. The test was done on single 
serum samples in duplicate according to the manufac-
turer’s instructions. The assay included a calibrator 
which defined the upper limit of the reference range in 
non-infected humans and this value was defined as the 
cut off. The assay was made semi-quantitative by calcu-
lating the ratio of the extinction of the patient sample/
extinction of the calibrator. Ratios < 0.8 were consid-
ered negative, those ≥ 1.1 as positive and those ≥ 0.8 
to < 1.1 regarded as borderline.
Statistical methods
Spearman correlation coefficient was calculated to 
assess the correlations between the different assays.
Figure 
Scatter plots comparing antibody titres obtained from different assays in relation to duration (days) after onset of illness due 
to Middle East respiratory syndrome (MERS)-coronavirus infection
ELISA: enzyme-linked immunosorbent assay; MN: microneutralisation; OD: optical density; PRNT: plaque reduction neutralisation test; ppNT: 
pseudoparticle neutralisation test.
Spearman correlation for each comparison is denoted in each panel. Sera collected 1–10; 11–20 and ≥ 21 days from onset of illness are 
denoted in yellow, green and blue, respectively. The MERS-spike ppNT, MN, PRNT50, and PRNT90 titres have been jittered for better 
presentation. The negative cut-off titres or OD is denoted in a dotted line.
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Results
Scatter-plots showing correlation between PRNT90, 
PRNT50, ppNT, MN and S1-ELISA assays are shown in 
Figure A-E. As expected, the PRNT50 assay was more 
sensitive than the PRNT90 because it uses the less strin-
gent end-point of 50% reduction in the plaque count 
(Figure A). There was excellent correlation between the 
PRNT90, MN and MERS-spike ppNT titres with Spearman 
correlations of 0.97–0.98 (Figure B,C). MERS-CoV S1 
ELISA was less strongly correlated with the different 
neutralisation assays with Spearman correlation of 
0.86–0.87 (Figure D and E).
Table 1 shows the proportion of sera that were positive 
in neutralising tests at titres ≥ 1:20 or in ELISA. None 
of the patients were seropositive in the first 10 days 
of illness. At 11–15 days of illness, 50% of sera were 
positive in PRNT50 assays, 39% in PRNT90 and S1-ELISA 
assays and 33% positive in ppNT and MN assays. 
After 21 days of illness, the majority of patients were 
seropositive. However, even at day 32 of illness, one 
patient remained seronegative in PRNT90, ppNT and 
MN assays, borderline positive in the S1 ELISA and 
was only positive in the PRNT50 test at a titre of 1:20. 
She was aged in her mid-fifties with no underlying dis-
eases, and presented with a relatively mild pneumonic 
illness (reported more fully in [9]).
Twelve patients seroconverted (fourfold increase in 
antibody titre) by all five assays and one had static high 
titres (first serum sample of this patient was at day 13 
of illness). The woman in her mid-fifties noted above 
failed to seroconvert by S1 ELISA, MN and PRNT90, and 
only reached PRNT50 antibody titre of 1:20 up to day 32 
of illness. Three other patients did not seroconvert in 
any of the assays, but the latest available sera from 
them was at day 8, 9 and 16, respectively, too early 
to conclude whether sera of these patients at a later 
stage of illness would have shown seroconversion.
In order to compare antigenic similarity of genetically 
diverse MERS-CoV, we selected four sera from two 
patients. These sera had been sampled early (day 12, 
17) and later (day 35, 39) during the course of illness. 
The antibody titres of each serum to clade A, clade B 
and the genetically divergent Egyptian camel viruses 
were within twofold (Table 2).
Discussion
The different virus neutralisation assays (MN; ppNT 
PRNT50; PRNT90) all had excellent correlation among 
them (Spearman correlation ≥ 0.94) (Figure). The PRNT50 
antibody test was more sensitive in detecting early 
antibody responses and had higher antibody titres 
Time periods in days 
from onset of illness
Number of serum 
samples 
Number of 
patients
Proportion of sera with neutralising antibody titres ≥ 1:20 
n/N ELISA positive
PRNT90 PRNT50 ppNT MN
1–5 7 7 0/7 0/7 0/6a 0/7 0/7
6–10 17 11 0/17 0/17 0/17 0/17 0/17
11–15 18 17 7/18 9/18 6/18 6/18 7/18
16–20 19 17 14/19 15/19 14/18a 14/19 15/19
≥ 21 34 9 33/34 34/34 31/33a 33/34 33/34
Table 1
Proportion of sera that were positive for antibodies to Middle East respiratory syndrome (MERS) in various assays at 
different times post-disease onset
ELISA: enzyme-linked immunosorbent assay; MN: microneutralisation; PRNT: plaque reduction neutralisation test; ppNT: pseudoparticle 
neutralisation test. 
a One serum in each of these groups could not be tested in the ppNT assay, thus the denominator for the ppNT differed from the others.
Patient ID Days of illness
Reciprocal PRNT90 antibody titre to MERS-CoV strains representing different MERS-CoV clades
Strain EMC 
(clade A)
Dromedary camel Al-Hasa KFU-HKU13 2013 
(clade B)
Dromedary camel Egypt NRCE-HKU 270 2013 
(clade non A/B)
B 12 320 160 160
B 39 320 320 640
G 17 40 40 80
G 35 160 80 160
Table 2
Antigenic cross-reactivity of human convalescent sera with genetically diverse MERS-CoV in 90% plaque reduction 
neutralisation tests (PRNT90)
ID: identity; MERS-CoV: Middle East respiratory syndrome (MERS)-coronavirus. 
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throughout, as would be expected, given the less strin-
gent end point of ≥ 50% reduction of plaque numbers, 
in contrast to the ≥ 90% reduction of plaques needed 
for the PRNT90 antibody titre endpoint (Figure A) (Table 
1). In studies of household transmission of MERS-CoV, 
it was shown that PRNT50 can detect some infections 
undetected by PRNT90 tests [12].
Unlike other neutralisation tests that require handling 
live MERS-CoV in biosafety level (BSL)-3 containment, 
the MERS-spike ppNT assay does not require BSL-3 
containment. It gave good correlation with PRNT90 and 
MN tests. We have previously shown that sera from 
healthy humans sera from Hong Kong (n = 115), Egypt 
(n = 100) and Saudi Arabia (n = 237) were negative in 
the ppNT test [5,13], confirming the specificity of this 
assay. Although the ppNT assay had been extensively 
used and validated for seroepidemiology in animals 
and livestock with good correlation between MERS 
ppNT and MN assays, [5,11,13], this is the first exten-
sive demonstration of its performance in humans with 
confirmed MERS-CoV infection and during the first six 
weeks of infection. ppNTs have proved to be reliable 
surrogates for neutralisation tests in other infections 
including avian influenza A(H5N1) [14]. Thus, the MERS-
spike ppNT may be usable for large scale seroepidemi-
ology studies to assess extent of MERS-CoV infection 
in the general population, to assess risk factors of 
infection in high-risk groups, or when selecting patient 
sera for plasmapheresis for preparation of convales-
cent plasma where quantification of neutralising anti-
body may be important.
The semi-quantitative optical density (OD) ratios of the 
MERS S1 ELISA had acceptable but lower Spearman 
correlations (0.86–0.87) with the different neutralisa-
tion tests, in terms of the time to becoming positive in 
patients with MERS (Figure D,E). The S1-ELISA assay 
was a binding assay detecting IgG alone, rather than 
a functional neutralising assay and thus the lower cor-
relation with this type of assay was not surprising.
In contrast to viruses such as avian influenza A(H5N1) 
where there is great antigenic diversity, genetically 
diverse MERS-CoV remain antigenically homogenous. 
Similar results had been previously reported using 
dromedary camel sera [11], and also clade B viruses 
and MERS-CoV EMC (clade A) were antigenically indis-
tinguishable with human sera [15].
The Korean outbreak was caused by a clade B virus. 
Limitations of this study are that all the sera tested were 
from one outbreak and from one ethnic background 
and that a MERS-CoV isolate from these patients was 
not available for use in the serology tests. However, we 
have demonstrated in this, and previous studies, that 
antibody titres are not affected by the clade of virus 
used. 
In conclusion, the different types of neutralisation or 
ppNT assays can be used in MERS-CoV diagnosis and 
seroepidemiology. PRNT50 was more sensitive than 
other assay formats and may be the only assay that 
can be positive early in the course of infection and in a 
few patients with poor serologic responses. Genetically 
diverse MERS-CoV are antigenically homogenous sug-
gesting that future vaccines generated by any MERS-
CoV strain will cross-protect against genetically and 
geographically diverse viruses.
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